A retrospective study to evaluate the predictive ability of a DNA methylation status-based diagnostic method for the sensitivity of anti-EGFR treatment for metastatic colorectal cancer
Not Applicable
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000041205
- Lead Sponsor
- Institute of Development, Aging and Cancer (IDAC), Tohoku University
- Brief Summary
DNA methylation status may be a predictor of therapeutic response to anti-EGFR antibody drugs in the first-line treatment of metastatic colorectal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 241
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who received anti-EGFR antibodies in the first or second line of treatment. Cases in which the patient is unable to submit the required amount of tissue samples from the primary tumor for measurement of methylation status. Cases considered by the attending physician to be unsuitable for enrollment in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method